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Introduction
LXRs are members of the nuclear receptor superfamily comprising several ligand-activated transcription factors. LXRs regulate gene transcription by binding as heterodimers with the 9-cis retinoic acid receptor (RXR), an obligate partner, to specific DNA sequences known as LXR-responsive elements (LXREs) located in the promoters of target genes [1] .
In the basal state and absence of ligand activation, the LXR/RXR heterodimer actively represses the transcription machinery of a number of target genes through interactions with corepressor complexes, such as the nuclear receptor corepressor (NcoR) and the related factor SMRT (silencing mediator of retinoic acid and thyroid hormone receptors), a concept supported by the enhanced basal expression of such LXR target genes in certain cells in the absence of receptor [2;3] . Binding of a ligand induces a conformational change in the protein, which leads to displacement of corepressors and results in the recruitment of coactivator proteins, such as steroid receptor coactivator (SRC)-1, Grip1 (a p160 family coactivator), or peroxisome-proliferator-activated receptor (PPAR)γ coactivator 1α (PGC-1α). These events thereby promote the transcription of target genes [4] .
Two LXR isotypes, LXRα and LXRβ, have been identified. LXRα is highly expressed in liver, and at lower levels in the intestine, macrophages, adipose tissue, lung, adrenal glands and kidney, while LXRβ is ubiquitously expressed [5] . While LXRα and LXRβ are very similar in structure and exhibit a particular high degree of homology between their ligand-binding domains (LBDs), their nuclear retention and localization as well as function display some differences [6] .
Both LXR isotypes are activated by physiological concentrations of oxidized derivatives of cholesterol (oxysterols) [7] , as well as by cholesterol precursor sterols [8;9] .
In addition, synthetic LXR ligands have been identified that are either pure agonists activating both LXR subtypes, or partial agonists exhibiting a LXR subtype-, tissue-and/or target gene-specificity.
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A c c e p t e d M a n u s c r i p -5 -LXRs play a critical role in the control of lipid metabolism, acting as regulators of cholesterol and fatty acid metabolism, and have been the topic of several recent reviews [10] . LXRs function as cholesterol sensors and regulators of a set of genes associated with cholesterol absorption, transport, efflux and excretion, and as such control whole body cholesterol homeostasis. The activation of LXRs results in an improved reverse cholesterol transport and increased circulating high-density lipoprotein (HDL) levels. In addition, LXRs act as master regulators of hepatic lipid metabolism. Of importance, however, synthetic LXR agonists may induce lipogenesis, leading to increased plasma triglyceride concentrations and hepatic steatosis. Hence, considering the importance of dyslipidemia as a risk factor for atherosclerosis and subsequent cardiovascular diseases, activation of the LXR pathway as a potential target for therapeutic intervention in human cardiovascular disease may be questioned. However, it has also been shown that treatment with LXR agonists attenuate the development of atherosclerosis in mouse models [11] [12] [13] [14] [15] , suggesting therefore that synthetic LXR agonists may be promising anti-atherosclerotic agents, despite a potentially adverse lipogenic effect. In this review, we discuss the therapeutic potential behind the development of LXR agonists, and the importance to identify novel therapeutic molecules that would act as selective LXR modulators, in order to obtain the desired cardioprotection and other benefits without causing liver fat accumulation.
LXRs : sensors of lipid metabolism

LXRs and cholesterol homeostasis
Although cholesterol is an essential component of cell membranes as well as the substrate for bile acid and steroid hormone synthesis, an excess of cellular cholesterol may be toxic and result in the development of atherosclerosis and subsequent cardiovascular diseases. A proper control of cholesterol homeostasis is therefore crucial.
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A c c e p t e d M a n u s c r i p -6 -LXRs play an important role in controlling cholesterol homeostasis via their coordinated effects on 1) intestinal dietary cholesterol absorption, 2) liver cholesterol biosynthesis and uptake, 3) HDL particle synthesis and remodelling, conditioning their subsequent activity in reverse cholesterol transport, 4) cholesterol elimination from the body by regulating, at least in rodents, its conversion by the liver into bile acids and excretion of cholesterol into the bile.
LXRs and dietary cholesterol absorption
It has been reported that LXRα agonists inhibit intestinal cholesterol absorption in mice. It was initially hypothesized that this effect is due to an increase of the ATPbinding cassette transporter (ABC) superfamily, subfamily A, member 1 (ABCA1) gene expression in the intestine [2] . However, since then, it has been demonstrated that ABCA1 is rather present on the basolateral membrane of enterocytes and, hence, does not mediate dietary cholesterol absorption but is rather involved in the generation of HDL [16] . Two other ABC sterol transporters, ABCG5 and ABCG8, localized on the apical membrane of intestinal cells have been shown to be LXR target genes [17] , but the direct role of these transporters in the decrease of cholesterol absorption upon LXR activation remains unclear.
Niemann-Pick C1 like 1 (NPC1L1) is a protein expressed in the brush border membrane of enterocytes in the small intestine and the molecular target of the cholesterol absorption inhibitor ezitimibe. NPC1L1 has been identified as an entero-transporter of dietary cholesterol [18] . A recent study performed in vitro, using a human enterocyte cell line, and in vivo in mice, has demonstrated that intestinal NPC1L1 expression is down-regulated by LXR [19] . All these data support a role of LXRs to decrease intestinal cholesterol absorption.
LXRs and liver cholesterol biosynthesis and uptake
One of the primary tissues in cholesterol metabolism is the liver, a key site of cholesterol biosynthesis and degradation. Moreover, the liver also acquires cholesterol of plasma low-density lipoproteins (LDL) via the LDL-receptor (LDLR). Intracellular cholesterol accumulation regulates both cholesterol biosynthesis and LDLR transcription
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A c c e p t e d M a n u s c r i p -7 -through a negative feedback mechanism involving the inhibition of the sterol regulatory element-binding protein (SREBP) family of transcription factors implicated in the regulation of lipogenesis and cholesterol metabolism [20] .
Using LXR-deficient mice fed a chow diet, it has been shown that LXRα-deficiency increases the expression of the cholesterol synthesis regulator SREBP-2, which in turn activates genes involved in cholesterol synthesis, such as HMG-CoA synthase and reductase, the rate-limiting enzyme in cholesterol synthesis in liver, and of enzymes downstream of the mevalonate pathway, including farnesyl diphosphate synthase and squalene synthase [21] . Smaller increases in the hepatic expression of these genes, except SREBP-2, were also observed in LXRβ-deficient mice [22] . However, very recent data suggest that LXRα can act as an inhibitor of cholesterol biosynthesis by directly silencing the expression of two cholesterogenic enzymes, the lanosterol 14α-demethylase (CYP51A1), and squalene synthase [23] . Finally, whereas no differences were seen in the regulation of LDLR gene expression in LXRα-deficient mice under basal conditions [21] , LXRα activation has been reported to induce expression of the LDLR gene in hepatoblastoma cells, in a SREBP-independent manner [24] . All together, these observations support evidence for an important role for LXRα in regulating cholesterol biosynthesis.
LXRs and reverse cholesterol transport
The reverse cholesterol transport (RCT) is a multi-step process by which there is net movement of cholesterol from peripheral tissues, such as macrophages, back to the liver via the plasma compartment. HDL acts as the acceptor and transport particle for effluxed cholesterol and as such occupies a central position in RCT. The first step of the RCT pathway consists in the uptake of cholesterol from cells by specific acceptors. ABCA1 is essential for this step since it initiates the formation of HDL by promoting the efflux of cholesterol and phospholipids to lipid-poor apolipoproteins (apo) such as apo A-I or apo E [25] . In the second step, the effluxed cholesterol is esterified by lecithin:cholesterolacyltransferase and moved to the centre of the HDL particle, transforming therefore nascent discoidal HDL particles into spherical HDL 3 particles. Next,
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A c c e p t e d M a n u s c r i p LXRs control the RCT by several potential mechanisms. Firstly, LXRs stimulate the mobilization of cholesterol from intracellular pools to the plasma membrane, hence enhancing the availability of cholesterol for efflux to extracellular acceptors [26;27] . Secondly, several apolipoproteins and lipid-modulating enzymes involved in cholesterol efflux and HDL remodeling are transcriptional targets for LXRs (Figure 1) . Indeed, LXRs stimulate the expression of apoE in mouse macrophages and adipose tissue, but not in the liver [28] , all genes of the apoC-I/apoC-IV/apoC-II gene cluster in human and murine macrophages [29] and apoA-IV in mouse liver and the human hepatoma HepG2 cell line [30] . Previous studies have demonstrated that LXR activation in cultured HepG2 cells or in vivo in mice, results in an increase of the expression and plasma activity of the enzyme catalyzing the exchange of phospholipids between HDL particles and triglyceride-rich lipoproteins, the phospholipid transfer protein (PLTP), leading therefore to an increased HDL-cholesterol level and HDL particle size [31;32] . LXRs activate human cholesterol ester transfer protein (CETP) gene expression [33] .
CETP facilitates cholesterol ester and triglyceride transfer between HDL and apoB-containing lipoprotein particles. Ii is not expressed in rodents, but in humans, CETP activity is inversely correlated with HDL-cholesterol levels, and this observation raises the question whether LXR agonists will increase HDL-cholesterol in humans. Indeed, a previous study showed that LXR agonist treatment does not increase HDL-cholesterol in human CETP transgenic mice [34] . Finally, the expression of lipoprotein lipase (LPL) which is the enzyme catalyzing the hydrolysis of lipoprotein triglycerides and which is involved in the maturation of HDL, is regulated by LXR [35] . This control is tissue-specific way, and LXR agonists induce expression of LPL in liver and macrophages, but not in adipose tissue [35] . Thirdly, LXRs enhance RCT via a direct action in macrophages ( Figure 1 ). ABCA1 does not directly interact with mature HDL that constitutes the bulk of the plasma HDL, and therefore its activity does not readily account for cholesterol efflux from foam cells to HDL which represents the major atheroprotective mechanism for HDL. Two other members of the ABC superfamily, ABCG1 and ABCG4, have been demonstrated as mediators of cholesterol efflux from cells to HDL [36] . ABCG1 is highly expressed in macrophages (more than ABCG4) and its activity probably underlies the relationship between HDL levels and atherosclerotic risk. Using different strategies, such as ligand-activation of LXRs [2;36-38] , analysis of cells that express a dominant-
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A c c e p t e d M a n u s c r i p -9 -negative form of LXRα or LXRβ [39] , peritoneal macrophages isolated from LXRα/β-deficient mice [2;40] , or small interfering (si)RNA [36] , it has been demonstrated that the increase of ABCA1, ABCG4 and/or ABCG1 expression is LXR-dependent, and that both LXR isotypes are implicated. Moreover, in mice fed a low-fat diet, LXRα-and LXRβ-deficiency results in a significant accumulation of cholesterol in macrophages of the spleen, lung and arterial wall, concomitantly with a decreased hepatic ABCA1 gene expression [41] . Also, recent data demonstrate that pharmacological activation of LXRs in vivo promotes RCT from cholesterol injected-loaded macrophages accompanied by upregulation of ABCA1, ABCG1, ABCG5 and ABCG8 in liver and intestine [42] .
LXRs and bile acid metabolism
Bile fluid contains water, cholesterol, phospholipids (mainly phosphatidylcholine), bile salts, bilirubin and bicarbonate ions. Bile acids are produced by the liver from cholesterol, and cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme of the neutral pathways. Bile acids are then conjugated to glycine or taurine prior to secretion into bile. The biliary secretion of lipid and bile salts is controlled by hepatic cholesterol, phospholipids and bile salt transporters located on the hepatocyte canalicular membrane. The bile salt export pump is the major canalicular bile salt export pump in mammalian liver. The human multidrug resistant 3p-glycoprotein, also known as ABCB4 (corresponding to the murine Mdr2 p-glycoprotein), translocates phosphatidylcholine molecules from the inner to the outer leaflet of the canalicular membrane. Finally, the functional complex ABCG5/G8 pumps cholesterol into bile. Cholesterol is only slightly soluble in aqueous solutions, but is made soluble in bile by bile salts and phospholipids, whose concentrations determine the degree of cholesterol saturation, corresponding to the cholesterol saturation index. Cholesterol gallstone disease, which accounts for nearly 80% of the gallstone diseases, results when disbalanced concentrations of cholesterol, phospholipids and bile salts in the bile provoke cholesterol crystal aggregation in gallbladder. During a meal, bile acids are released into the duodenum. The vast majority are subsequently reabsorbed throughout the intestine and return via the portal blood to the liver, where they exert a negative retrocontrol on bile acid synthesis. Recirculated bile acids are secreted again into bile after a meal. A fraction of bile acids escape intestinal absorption and are secreted in feces. This constitutes the main physiological way of cholesterol elimination from the body. The enterohepatic circulation and the feedback Page 10 of 35 A c c e p t e d M a n u s c r i p -10 -regulatory loop of bile acid synthesis as well as their excretion are essential mechanisms for the maintenance of cholesterol and bile acid homeostasis, preventing bile acid accumulation and avoiding therefore their toxicity as well as cholestasis. These different steps of bile acid metabolism are tightly controlled by a complementary and coordinated action of LXR and the Farnesoid X Receptor (FXR) which acts as the bile acid sensor [43] .
In rodents, cholesterol accumulation in the liver induces a feed-forward activation of CYP7A1, which is mediated by LXRα [7] . Using LXRα-and LXRβ-deficient mice, direct evidence for the role of LXRα in bile acid synthesis was provided [21] , suggesting again a less important role of LXRβ in this effect [22] . Hepatic expression of ABCG5/G8 is increased upon LXR activation, and this results in an enhanced hepatobiliary excretion of cholesterol as well as an increased fecal neutral sterol excretion [44;45] . Thus the enterohepatic circulation and the regulatory feedback loop of bile acid synthesis as well as the excretion of their excess are essential mechanisms for the maintenance of cholesterol and bile acid homeostasis in which LXR play an important role. Interestingly, it has been demonstrated in vivo in mice that activation of LXRs prevents bile acid toxicity and cholestasis in female mice, which is associated with an increased expression of bile acid-detoxifying genes and a regulation of certain bile acid transporters [46] . Nevertheless, and despite this favourable effect of LXR, very recently, it has been shown that activation of LXR promotes cholesterol crystallisation [47] . This lithogenic effect of LXR is associated with dysregulation of hepatic transporters resulting in a combined effect of increased biliary concentrations of cholesterol and phospholipids and decreased biliary concentrations of bile salts, leading therefore to an increased cholesterol saturation index. However, the relevance of these anticholestatic and lithogenic effects of LXR to the human situation is not known. Indeed, it was demonstrated that in contrast to rodents, human CYP7A1 expression is not regulated by LXR in vitro in HepG2 cells [48] . Moreover, recently, it has been shown that LXR activation suppresses the expression of the enzyme in human primary hepatocytes [49] . Hence, it cannot be excluded that, in humans, LXR activation could potentially increase the risk of hepatic cholestasis.
LXRs and fatty acid metabolism
Page 11 of 35 A c c e p t e d M a n u s c r i p -11 -Besides the role of LXRs in cholesterol homeostasis, LXR activation also increases the expression of genes of fatty acid biosynthesis (lipogenesis), and raises plasma triglyceride levels (hypertriglyceridemia) [50] [51] (Figure 2 ). This activity is demonstrated both using LXR-deficient mice, and/or pharmacological treatment of mice with a LXR agonist, in rodent as well as in human hepatocytes [49;52] . Moreover, activation of LXRs also promotes triglyceride accumulation in other cell types such as human skeletal muscle cells [53] or pancreatic β-cells (islets from diabetic rodent models or INS-1 insulinoma cells) [54] .
Severe hepatic steatosis develops in mice upon LXR agonist treatment, and many studies explained this effect by a direct up-regulation of SREBP1c, the major SREBP1 isoform, in the liver which stimulates the transcription of lipogenic genes such as fatty acid synthase (FAS), acetyl-coA carboxylase (ACC) and stearoyl-coenzyme A desaturase 1 (SCD1) (a rate-limiting enzyme necessary for the biosynthesis of monounsaturated acids) [21;50;52;55;56] . In addition, some evidence indicates the ability of LXR to directly target expression of lipogenic genes, such as FAS [57] , ACC [56] , SCD1 [58] and the carbohydrate response element binding protein (ChREBP) [59] (a glucosesensitive transcription factor that promotes the hepatic conversion of carbohydrates into lipids). Finally, it has been shown that activation of LXR in vivo in mice results in the induction of the liver-specific uridine phosphorylase gene (L-UrdPase), an enzyme involved in the pathway of nucleotide biosynthesis and the regulation of plasma uridine levels, suggesting therefore a possible role for LXRs in the maintenance of uridine homeostasis [60] . Since β-alanine, a major product of uridine catabolism is a precursor of fatty acid synthesis, and although no evidence for a direct regulatory pathway of L-UrdPase gene regulation by LXRs has yet been provided, it is possible that LXR regulation of this gene participates in the mechanism of LXR-induction of lipogenesis.
Apart from the induction of hepatic steatosis, it has been reported that pharmacological LXR activation in mice results in elevated plasma triglycerides [50] and promotes pathways of very low density lipoprotein-triglyceride secretion [51] . Despite the fact that the mechanisms are not well understood, studies have uncovered several important proteins that could mediate the LXR-mediated hypertriglyceridemic effect. These include SREBP-1c and angiopoietin-like protein 3 (Angptl3) [61] (a liver-secreted protein that increases both plasma triglycerides by inhibiting LPL activity in different tissues, and free fatty acids by activating lipolysis in adipocytes) whose expression is increased, and/or apoA-V which is down-regulated by LXR activation [62] .
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A c c e p t e d M a n u s c r i p -12 -Despite the fact that LXR activation leads to severe lipid overloading in non-adipose tissues, severe hepatic steatosis and accumulation of lipid in muscle cells, conditions usually associated with insulin resistance and type 2 diabetes, this does not result in any apparent deleterious effect on hepatic insulin sensitivity [63] or insulin action [53] . However, the long-term consequences of triglyceride accumulation upon LXR activation in muscle have yet to be evaluated. On the other hand, it has been shown that, upon chronic activation by LXR agonists, lipid overloading in pancreatic β-cells causes serious β-cell dysfunction and apoptosis, a significant process in the development of type 2 diabetes [54] .
LXR-induced lipogenesis hampers the development of LXR agonists as novel therapeutics, and a thorough knowledge on the different roles that the two LXR subtypes play in this process is crucial for the design of improved selective molecules. Previous studies show that in vivo in mice, both LXRα and LXRβ isoforms are implicated in the fatty acid synthesis pathway [50;55] , with a more prominent implication of LXRα [21;22] . However, other reports suggest that the LXRβ isoform may be the more important isoform for lipogenesis and plasma triglyceride metabolism up-regulation [41] .
Factors determining the transcriptional activity of LXRs
Tissue-specific regulation of certain genes by LXRs exists, exemplified by the regulation of the apoE gene in adipose tissue and macrophages but not in liver [28] , or the induction of LPL only in liver and macrophages but not in adipose tissue [35] . Although the precise molecular basis for this regulation is unknown, several mechanisms could contribute to this specificity. The first and more evident factor that determines the transcriptional selectivity of the LXR isotypes is their respective tissue distribution.
Indeed, since LXRα is expressed in liver to a higher extent than LXRβ [5] , it appears that the undesirable stimulation of lipogenesis by LXR ligands may be primarily mediated by LXRα. A second factor determining cellular transcriptional specificity of LXRs relates to the concept of Selective LXR Modulator (SLXRM). Indeed, differential regulation
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A c c e p t e d M a n u s c r i p -13 -of LXR target genes due to distinct corepressor recruitment has been described. For example, the SREBP1c and the ABCA1 genes exhibit a striking difference in the way LXRs regulate their promoter activity [3] . While the absence of LXRs in mice causes derepression of basal ABCA1 expression in macrophages and the intestine, this derepressive effect does not occur on the SREBP1c promoter. This is thought to result from a differential recruitment of the corepressors NcoR and SMRT to the ABCA1 but not the SREBP1c promoters. Moreover, differences in intracellular levels of coactivators and corepressors between different cells occur that could result in certain target cell-specific LXR responses [64] . Also, certain cofactors, such as receptor interacting protein (RIP) 140, can act in liver either as coactivator or corepressor, depending upon the LXR target genes [65] .
LXR ligands : approaches for the development as therapeutic agents
The identification of high-affinity synthetic agonists for nuclear receptors has enabled many studies on the biological functions of these nuclear receptors. The availability of antagonists has also been important to demonstrate that a given effect is indeed mediated by a nuclear receptor. However, the development of pure agonists and antagonists are only rarely the goal in therapeutic strategies based on nuclear receptors as drug targets, when attempting to improve the pharmacological profile of new molecules. In most cases, partial and selective modulators (agonists or antagonists) are desired, which activate or block the receptor in a tissue-specific manner and/or present target-gene specificity. The prototypic examples for such selective nuclear receptor modulators are tamoxifen and raloxifen which are selective estrogen receptor (ER) modulators (SERMs). These drugs activate or inhibit the ER, therefore enabling estrogen-like stimulation in brain, bone and potentially the cardiovascular system, while inhibiting the responses to estrogen in breast and prostate.
LXR activators
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A c c e p t e d M a n u s c r i p -14 -While cholesterol itself has no effect on LXR activity, oxidized cholesterol derivatives (oxysterols) activate LXRs, with the most potent activators being the naturally occurring 22(R)-hydroxycholesterol, 20(S)-hydroxycholesterol, 24(S),25-epoxycholesterol, and 27-hydroxycholesterol [7;66;67] . Importantly, these oxysterols elicit a LXR response at concentrations consistent with those found in tissue extracts [7;68] . Moreover, it has been argued that certain oxysterols, such as 27-hydroxycholesterol or the synthetic oxysterol N,N-dimethyl-3β-hydroxycholenamide, may be cell-specific physiological LXR ligands [69;70] , and recently it has been shown that oxysterols may present LXR target-gene specificity in vivo [71] .
Most of the endogenous LXR ligands identified so far activate both LXRα and LXRβ. However, the oxysterol 5,6-24(S),25-diepoxycholesterol is a relatively selective LXRα ligand, suggesting the feasibility of developing subtype-selective LXR ligands for pharmacological applications [68] . In addition, natural and synthetic 6α-hydroxy bile acids are more selective activators of LXRα than LXRβ [72] . Moreover, cholestenoic acid, a metabolite of 27-hydroxycholesterol, is a naturally occurring ligand for LXRα, but not for LXRβ [73] .
In addition to endogenous ligands, a number of synthetic LXR ligands have been developed. Most of them are dual agonists, activating both LXRα and LXRβ, and present both the favourable effects on cholesterol metabolism and the unfavourable effects on fatty acid metabolism. Treating mice deficient in either LXRα, LXRβ or both, with an agonist displaying equal potency for both isoforms or an agonist selective for LXRα, demonstrated that specific activation of LXRα or LXRβ yields distinctive lipid outcomes in vivo [74] . Most importantly, this study lends further support to the hypothesis that a specific agonist of LXRβ would raise plasma HDL-cholesterol levels and increase the expression of ABCA1 in macrophages (stimulating therefore cholesterol efflux), without causing liver triglyceride accumulation. This particular interest for LXRβ has been supported by another study in which selective activation of this isotype by treatment of LXRα-deficient mice with a dual agonist results in a strongly decreased expression of hepatic genes concomitant with an increased expression of both the ABCA1 and SREBP1c genes in peripheral tissues (kidney and duodenum), causing plasma HDL increases without hypertriglyceridemia [75] .
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A c c e p t e d M a n u s c r i p [50] and GW3965, [3-(3-(2-chloro-3-trifluoromethyl-benzyl-2,2-diphenyl-ethylamino)propoxy) phenylacetic acid] (GlaxoSmithKline Pharmaceuticals) [76] are structurally distinct and present some differences in their biological activity. In cell-based studies, GW3965 is a relatively weak activator of LXRs compared to T0901317, and this is particularly pronounced for LXRα in human hepatoma cells. While in vivo, in mice, both compounds generally increase rate of RCT and improve cholesterol homeostasis, their effects on fatty acid metabolism are different (Table 1) . Moreover, in vivo, in mice, GW3965 behaves as a selective modulator of LXRα activity in liver [77] .
Indeed, whereas both T0901317 and GW3965 induce ABCA1 expression to similar extents in the small intestine, in liver, T0901317 significantly induces FAS and ABCA1 whereas GW3965 has limited effects. These observations are reflected by increased HDL-cholesterol levels in mice treated with T0901317 or GW3965, whereas the induction of steatosis occurs only in mice treated with T0901317. This tissue-specific induction by GW3965 of intestinal rather than hepatic LXR genes was confirmed in mice with liveror intestinal-specific deletion of the Abca1 gene [78] . Different patterns of coactivator recruitment between T0901317 and GW3965 may account for their tissue selectivity [77] .
However, it is not so clear whether GW3965 can be defined as a tissue-specific LXR agonist regulating non-hepatic genes and improving cholesterol metabolism while avoiding deleterious lipogenic effects, since data from other in vivo studies evidenced an increased hepatic triglyceride content and/or an hypertriglyceridemia after treatment with this compound [11;63;70] .
The discovery of the crucial role that LXRs play in cholesterol metabolism has resulted in an interest to design novel chemical entities acting as LXR ligands for potential therapeutic intervention in atherosclerosis, particularly as HDL inducers. Structure-activity relationship (SAR) studies have been therefore conducted, resulting in the synthesis of different LXR agonists. Among them are acetyl-podocarpic acid and derivatives [79;80] , 2-aryl-N-acyl indole [81] , or N-acylthiadiazolines [82] , anilinohexafluoroisopropanols [83] , phenyl acetic acid substituted quinolines [12] , acanthoic acid-related diterpenes [84] , acidic heterocycles [85] . However, although most of these compounds are active on cholesterol metabolism, they also undesirably upregulate SREBP1-c gene expression, limiting therefore their development. Interestingly, two synthetic steroidal LXR agonists, ATI-829, [3α, 6α,24-trihydroxy-24, 24-di(trifluromethyl)-5β-cholane] (Anagen Therapeutics Inc.) [13] [86] . In THP-1 cells, RC binds directly to LXRα and recruits the coactivator SRC-1, leading therefore to the activation of LXRα-dependent reporter genes. RC also possesses the ability to bind LXRβ but its inability to recruit coactivators results in the failure of LXRβ-mediated transactivation. RC induces ABCA1 and ABCG1 expression, resulting in an enhanced cholesterol efflux, and increases SREBP1c mRNA level in THP-1 cells while the compound has no effect on SREBP1-c and ABCG1 expression in HepG2 cells. Although studies are required to elucidate the precise mechanisms of RC's selective actions, these data suggest that LXR modulators which do not upregulate hepatic lipogenic genes may lead to improved therapeutic strategies.
LXR antagonists
Geranylgeranyl-PP, a major product of farnesyl-PP which represents a key branch in the mevalonic pathway for the cholesterol synthesis, negatively regulates LXRα and LXRβ transcriptional activity by interfering with LXR-coactivator interaction [67] . Unsaturated fatty acids have been demonstrated to inhibit LXR activation of SREBP1-c by antagonizing ligand-dependent activation of LXR [87] or inhibiting LXR binding to a LXRE [88] . Finally, plasma from hypercholesterolemic patients contains elevated concentrations of oxidized cholesterol 3-sulfates that could act as natural antagonists of LXRα and LXRβ [89] .
Recently, it has been reported that methanol extracts from plants used in oriental medicine present in vitro selective LXRα inhibitory activity with insignificant effects on LXRβ activity [90] . Two of these extracts, MEH184 and MEH185 suppress the transcriptional activity of LXRα as well as the expression of LXRα target genes, exerting repressive effects on 3T3-L1 adipocyte differentiation and triglyceride accumulation without significant changes in cellular cholesterol level.
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LXR ligands : promises for atherosclerosis treatment
Intervention studies in murine models support the hypothesis that drugs which target LXRs may offer benefits in the treatment of atherosclerosis. Indeed, administration of LXR ligands to apoE-or LDR-deficient mice clearly demonstrated that LXR activation results in a significant reduction of atherosclerosis [11] [12] [13] [14] [15] . Moreover, results from bone marrow transplantation experiments showed that loss of LXR function in macrophages resulted in an increased lesion formation in apoE-deficient [91] or LDLR-deficient mice [92] . Importantly, recent results demonstrate that treatment of mice lacking both apoE and LXRα with a synthetic LXR ligand ameliorates cholesterol homeostasis and reduces atherosclerosis, providing therefore evidence for the ability of LXRβ to compensate for the loss of LXRα [93] . These data provide support for further selective targeting of LXRβ to identify drugs for the treatment of atherosclerosis. The anti-atherogenic effect of LXRs can be mediated by metabolic regulation, e.g. an increased HDL formation and an improved macrophage cholesterol metabolism, but also by a direct protective action on the artery wall via inhibition of inflammatory responses, particularly in macrophages [92] . This anti-inflammatory action of LXR activation appears to be mediated through repression of nuclear factor-κB (NF-κB) signalling and subsequent inhibition of the expression of target genes of NF-κB, such as interleukin-6 or matrix metalloproteinase-9 [94] . LXR ligands repress these genes in macrophages derived from wild-type, LXRα-or LXRβ-deficient mice but are unable to do so in macrophages from LXRα/β-deficient mice, indicating that both LXR isoforms possess anti-inflammatory activities. Moreover, subsequent work has suggested that tissue factor and osteopontin, both inflammatory response genes associated with an increased risk for developing atherosclerosis, are subject to similar repression by LXR ligands in macrophages [95;96] . Recently, it has been demonstrated that 48-hour pretreatment with LXR agonists leads to an increase in Toll-like receptor (TLR)-4 expression in human macrophages, resulting in an enhanced responsiveness of macrophages to lipopolysaccharide (LPS) (a chief pathogen-associated molecular pattern from Gram-negative bacteria), and an increased secretion of cytokines that activate an immune adaptive inflammatory response [97] . In addition, through enhancement of NADPH oxidase subunit expression, LPS-activated macrophages produce toxic reactive oxygen species (ROS), which could directly kill bacteria [97] . Thus, all these data identify a novel role for LXR in the preparation of macrophages to exert antibacterial activities.
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A c c e p t e d M a n u s c r i p -18 -Progression of immune response is also regulated at the level of macrophage survival. It has been shown that upregulation of the apoptosis inhibitory factor (AIM), also called Spα or Api6, in mouse lesion macrophages in response to specific activation of the LXRα isoform facilitates macrophage survival against different apoptosisinducing stimuli such as bacterial pathogens [98;99] . This macrophage survival pathway is very important in atherogenesis since it participates in foam cell formation, a characteristic of the early atherosclerotic lesion. Interestingly, AIM deficiency results in a protection from atherosclerosis [98] . It can be hypothesized that the anti-apoptotic effects of AIM contrasts with the other LXR/RXR-dependent gene effects that are atheroprotective, such as the critical role of LXR in cholesterol efflux from macrophages.
Indeed, an uncontrolled lipid accumulation in LXR-deficient macrophages increases atherosclerosis susceptibility, despite the increased rate of macrophage apoptosis. However, inducing macrophage apoptosis may contribute to the development of the lesion necrotic lipid core, thus potentially leading to the destabilization of the atherosclerotic plaque.
The anti-apoptotic effect of LXR-induced AIM could be therefore beneficial for atherosclerotic complications. Moreover, loss of macrophages might promote a proatherogenic environment, due to, for example, decreased production of apoE and reduced scavenging of toxic substances such as oxidized LDL. The relevance of the role of LXRα signalling on the macrophage survival pathway for human macrophages remains to be studied.
Conclusion and perspectives
In conclusion, as a transcriptional regulator of genes implicated in RCT and hepatic cholesterol catabolism, both LXRα and LXRβ have emerged as attractive targets to design new drugs in the field of cardiovascular disease. However, beside these desirable pharmacologic effects, undesirable effects such as an increased hepatic lipogenesis, currently hamper the development of LXR agonists. LXRα is the dominant isoform involved in the control of hepatic lipogenesis, and some data argue in favour of a preferential selective LXRβ activation as a mean to limit LXR-induced lipogenesis in liver. Importantly, it appears that both isoforms are implicated in the favourable effects of A c c e p t e d M a n u s c r i p t 
